North East and North Cumbria
ICS Formulary
ICS Formulary
5 Infections
05-03-01 Protease inhibitors
| Atazanavir |
|
Formulary
|
|
|
| Atazanavir sulfate and cobicistat |
|
Formulary
|
To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614). |
|
|
| Darunavir and Cobicistat |
|
Formulary
|
To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614). |
|
|
Links
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages)- COVID-19 Therapeutic Alert
- Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients (Version 5 - effective from 10th February 2022)
- MHRA Drug Safety Updates: Antiretroviral Medicines
- NENC ICB - Cellulitis Diagnosis and Management in Ambulatory Adults in primary care; Supporting Information
- NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
- NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population
- NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
- North of Tyne, Gateshead and North Cumbria - Antibiotic and Diagnostic quick reference tools
- Primary Care Antimicrobial Guidelines
- TEWV: Antibiotic Prescribing Procedure
- UK Interim Clinical Commissioning Police - Therapies for patients with symptomatic hospital-onset COVID-19